<DOC>
	<DOCNO>NCT02305017</DOCNO>
	<brief_summary>Single-centre , open-label , randomised , two-way cross-over study consist 2 period separate washout period 14 day .</brief_summary>
	<brief_title>Effect Paracetamol Opicapone Pharmacokinetics Healthy Volunteers</brief_title>
	<detailed_description>Single-centre , open-label , randomised , two-way cross-over study consist 2 period separate washout period 14 day . In one period , subject receive three single-doses 1 g paracetamol separate 6 hour 1.5 hour last paracetamol dose single-dose 50 mg OPC administered.In period , single-dose 50 mg OPC administer alone .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Subjects able willing give write informed consent . Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19.0 30.0 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead ECG . Subjects negative test HBsAg , antiHCVAb HIV1 HIV2 Ab screen . Subjects clinical laboratory test result clinically acceptable screen admission treatment period . Subjects negative screen alcohol drug abuse screen admission treatment period . Subjects nonsmokers exsmokers least 3 month . ( If female ) She childbearing potential reason surgery , childbearing potential , use effective nonhormonal method contraception ( intrauterine device intrauterine system ; condom occlusive cap [ diaphragm cervical vault cap ] spermicidal foam gel film cream suppository ; true abstinence ; vasectomize male partner , provide sole partner subject ) duration study . ( If female ) She negative serum pregnancy test screen negative urine pregnancy test Day 1 treatment period . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant abnormality coagulation test . Subjects clinically relevant abnormality liver function test ( casebycase decision abnormality must discuss Sponsor inclusion ) . Subjects history relevant atopy drug hypersensitivity , particularly paracetamol COMT inhibitor . Subjects history alcoholism drug abuse . Subjects consume 14 unit alcohol week . Subjects significant infection know inflammatory process screen admission treatment period . Subjects acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission treatment period . Subjects receive paracetamol within 2 week admission first period . Subjects use medicine within 2 week admission first period may affect safety study assessment , investigator 's opinion . Subjects previously receive OPC . Subjects use investigational drug participate clinical trial within 90 day prior screen . Subjects participate 2 clinical trial within 12 month prior screen . Subjects donate received blood blood product within 3 month prior screen . Subjects vegetarian , vegan medical dietary restriction . Subjects communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use approve effective contraceptive method use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>